• Earlier in April, Illumina announced DRAGEN v4.5, a major upgrade to its genomic analysis software that enhances accuracy, expands pangenome representation, and adds machine-learning-driven oncology and multiomic capabilities, including oncovirus detection and support for TruPath Genome.
• A separate data partnership with the Center for Data-Driven Discovery in Biomedicine is using Illumina’s DRAGEN and cloud tools to process 100,000 pediatric whole genomes, creating one of the largest unified datasets for cancer and rare disease research and reinforcing Illumina’s role in large-scale clinical genomics.
• We’ll now examine how DRAGEN v4.5’s machine-learning-driven oncology and multiomic enhancements influence Illumina’s existing investment narrative and expectations.

Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Illumina Investment Narrative Recap

To own Illumina, you need to believe that next generation sequencing and multiomic data will remain central to clinical and research workflows, and that Illumina can defend its installed base while expanding into software and analytics. DRAGEN v4.5 and the D3b partnership both support that software and data angle, but they do not materially change the near term focus on stabilizing instrument demand and managing competitive and geopolitical pressures.

The D3b collaboration, which uses DRAGEN and Illumina Connected Analytics to process 100,000 pediatric whole genomes, looks especially relevant here. It shows how Illumina’s secondary analysis and cloud tools can become embedded in large, clinically oriented datasets, reinforcing a recurring software and data role that aligns with existing catalysts tied to clinical sequencing and multiomic adoption.

However, against this backdrop, investors should also be aware that the biggest risk may be that...

Illumina's narrative projects $5.0 billion revenue and $1.0 billion earnings by 2029.

Uncover how Illumina's forecasts yield a $136.11 fair value, a 6% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts paint a far more cautious picture, with revenue growth at only about 2.6% a year and profits shrinking to around US$697.0 million, so it is worth considering how those expectations might change in light of Illumina’s new DRAGEN v4.5 capabilities and multiomic ambitions.

Explore 4 other fair value estimates on Illumina - why the stock might be worth as much as 22% more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Illumina research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Illumina research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Illumina's overall financial health at a glance.

Ready For A Different Approach?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 17 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.